There was a significantly lower proportion of patients in clinical recurrence in the ADA group ( 12.5 % ) compared with the AZA ( 64.7 % ; OR = 0.078 ( 95 % CI 0.013-0 .464 ) ) and mesalamine groups ( 50 % ; ( OR = 0.143 ( 95 % CI 0.025-0 .819 ) ) .
